Concert Pharmaceuticals, Inc.

Vistagen Therapeutics, Inc.

Qaam Pharmaceuticals, LLC

S&b Pharma, Inc.

Emerich Eisenreich

Xuejun Karl Liu

Daniel Levin

Steven A Weissman

Ramanaiah C Kanamarlapudi

Daniel A Dickman

Satish Puppali

Steven A Rich

Bingidimi Itute Mobele

Peter Leeming

Mackenzie Marrs

The invention relates to an overall enantio-specific synthesis of 4-chlorokynurenine compounds, in particular L-4-chlorokynurenine, with improved yields. Large-scale syntheses are disclosed. The invention also relates to novel intermediates in the synthesis of L-4-chlorokynurenine.

Synthesis of 4-chlorokynurenines and intermediates

Novel glycopyrronium fatty acid salts have been developed. Bi-phasic reaction conditions enable the desired counterion exchange reactions between glycopyrronium bromide and fatty acid salts of alkali metals and alkaline earth metals in methods to form glycopyrronium fatty acid salts. In preferred embodiments, an excess of the free fatty acid in the reaction mixture stabilizes the glycopyrronium fatty acid salt and reduces the formation of the impurity, Acid A. In some preferred embodiments, between 0.2 and 1.2 molar equivalent of excess free fatty acid is added to the reaction mixture. In another embodiment, approximately 1.2 molar equivalent of excess free fatty acid is added to the reaction mixture.

Glycopyrronium fatty acid salts and methods of making same

Solid cannabidivarin, crystalline cannabidivarin, (R,R)-(&#x2212;)-crystalline cannabidivarin, (S,S)-(+)-crystalline cannabidivarin and substantially pure forms thereof are disclosed herein. Further disclosed are methods of making such cannabidivarin, compositions and formulations comprising such cannabidivarin, and methods of treating disease with such cannabidivarin.

Crystalline cannabidivarin

The present invention provides a convenient and efficient process for the preparation of enantiomerically enriched, deuterated secondary alcohols without reducing deuterium incorporation.

Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation

The present invention provides a process for the preparation of enantiomerically enriched, deuterated secondary alcohols of Formula 1-A by employing ketoreductases or carbonyl reductases without reducing deuterium incorporation. 

Growing community of inventors

Claremont, CA, United States of America

Emerich Eisenreich